The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Novartis; Roche
Research Funding - Merck
Travel, Accommodations, Expenses - Novartis
Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (METAmp/Ex14∆).
 
D. Ross Camidge
Honoraria - Abbvie; Achilles Therapeutics; Apollomics; Archer; Arrys/Kyn; AstraZeneca; BeyondSpring Pharmaceuticals; bio-thera; Blueprint Medicines; Bristol-Myers Squibb; CBT pharmaceuticals; Daiichi Sankyo; Elevation Oncology; EMD Serono; G1 therapeutics; Hansoh; Helsinn Therapeutics; Hengrui Pharmaceutical; Inivata; Lilly; medtronic; regeneron; Ribon Therapeutics; Roche; takeda
Research Funding - Takeda
 
Filip Janku
Stock and Other Ownership Interests - Trovagene
Consulting or Advisory Role - Deciphera; Foundation Medicine; Guardant Health; IDEAYA Biosciences; IDEAYA Biosciences; IFM Therapeutics; Immunome; Jazz Pharmaceuticals; Novartis; PureTech; Sequenom; Sotio; Synlogic; Trovagene; Valeant/Dendreon
Research Funding - Agios (Inst); Asana Biosciences (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); Fujifilm (Inst); Genentech (Inst); Novartis (Inst); Piqur (Inst); Plexxikon (Inst); Proximagen (Inst); Roche (Inst); Symphogen (Inst)
Other Relationship - Bio-Rad
 
Alejandro Martinez-Bueno
Consulting or Advisory Role - Tesaro
Travel, Accommodations, Expenses - Roche
 
Daniel V.T. Catenacci
Honoraria - Amgen; Astellas Pharma; Bristol-Myers Squibb; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; Gritstone Bio; Guardant Health; Lilly; Merck; Seagen; Taiho Pharmaceutical; Tempus
Consulting or Advisory Role - Amgen; Astellas Pharma; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck; Seagen; Taiho Pharmaceutical
Speakers' Bureau - Foundation Medicine; Genentech; Guardant Health; Lilly; Merck; Tempus
 
Jeeyun Lee
Consulting or Advisory Role - Oncologie; Seagen
Research Funding - AstraZeneca; Lilly; Merck Sharp & Dohme
 
Se-Hoon Lee
No Relationships to Disclose
 
Afshin Dowlati
Consulting or Advisory Role - Abbvie/Stemcentrx; AstraZeneca; Bristol-Myers Squibb; Seagen; Takeda
Research Funding - Abbvie/Stemcentrx (Inst); Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Ipsen (Inst); Lilly/ImClone (Inst); Mirati Therapeutics (Inst); Regeneron (Inst); Seagen (Inst); Symphogen (Inst); Takeda (Inst); Tesaro (Inst); United Therapeutics (Inst)
 
Kristoffer Staal Rohrberg
Research Funding - Alligator Bioscience (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Cantargia AB (Inst); Genmab (Inst); Incyte (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Orion Clinical (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Symphogen (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Alejandro Navarro
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Pfizer; Roche
Expert Testimony - Oryzon Genomics
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer
 
Yong Wha Moon
No Relationships to Disclose
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; Achilles Therapeutics; ARIAD; AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Foundation Medicine; Genentech; Gritstone Bio; Hengrui Therapeutics; Maverick Therapeutics; Merck; Nektar; Neon Therapeutics; Novartis; Pfizer; Syndax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst)
 
Rebecca Suk Heist
Honoraria - Chugai/Roche
Consulting or Advisory Role - Apollomics; Boehringer Ingelheim; Novartis; Tarveda Therapeutics
Research Funding - Abbvie (Inst); Agios (Inst); Celgene (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Exelixis (Inst); Exelixis (Inst); Incyte (Inst); Lilly (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Turning Point Therapeutics (Inst)
 
Thomas Tuxen Poulsen
Employment - Symphogen
 
Arielle Yablonovitch
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
 
Lindsay Fosler
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
 
Helle Rudbaek
No Relationships to Disclose
 
Frank Nygaard
Employment - Symphogen
 
Debra L. Wood
Leadership - Forbius (I)
Consulting or Advisory Role - Forbius; Karyopharm Therapeutics (I); PRISM BioLab; Symphogen; Tessa Therapeutics
 
Rita P. Dalal
Employment - Daiichi Sankyo; Pfizer (I); Pfizer (I); Symphogen
Stock and Other Ownership Interests - Lilly; Merck Sharp & Dohme; Pfizer (I)
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; AstraZeneca; BerGenBio; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Janssen; Lilly; Medscape; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; priME Oncology; Roche; Samsung; Takeda; touchIME
Speakers' Bureau - Abbvie; AbbVie; AstraZeneca; BerGenBio; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Janssen; Lilly; medscape; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Prime Oncology; Roche; Samsung; Takeda; touchIME
Research Funding - EMD Serono (Inst); Merck (Inst)
Other Relationship - GRÍFOLS